Boundary Capital has announced its latest investment in Toxibact, a disruptive technology which has the potential to kill a wide range of microorganisms including bacteria and fungi with little prospect of them being able to develop resistance.
Toxibact has a novel potential antimicrobial therapy for the treatment of all bacteria - both ‘gram positive’ and ‘gram negative’ - and fungi. The drug was conceived and developed after independent, private research. Its unique mode of operation means it is not possible for the microorganisms to develop resistance.
It was announced earlier this year that a strain of bacteria was identified as untreatable by penicillin. The technology from Toxibact could potentially prevent cases such as this from occurring.
Boundary Capital’s model is to appoint experienced, investing directors as Venturers typically acting as executives directors or Chairman and assisting with commercialisation as well as helping to de-risk the proposition for investors and entrepreneurs alike. Dr Adrian Parton MBE, whose MBE was awarded for ‘Services to microbiology’, is also a Partner at Boundary Capital, is the Venturer on Toxibact.
Parton says: “1.5 million people die from TB every year and 2 billion people are affected worldwide. This is just one of the major bacterial diseases and our ability to rely on modern antibiotics is becoming more uncertain. I’m very excited to be involved with Toxibact which promises a sustainable and effective fight against a wide range of microbial infections.”
Dan Somers, the Managing Partner of Boundary Capital says: “We’re delighted to invest in this technology and with our experienced Venturer to help to productise and take it to market.”
